166 related articles for article (PubMed ID: 22125946)
1. Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method.
Czerwińska K; Mazurek AP
Acta Pol Pharm; 2011; 68(6):831-7. PubMed ID: 22125946
[TBL] [Abstract][Full Text] [Related]
2. HPLC method transfer study for simultaneous determination of seven angiotensin II receptor blockers.
Marghany KA; Abdelsalam RA; Haddad GM
J Sep Sci; 2020 Apr; 43(8):1398-1405. PubMed ID: 31991050
[TBL] [Abstract][Full Text] [Related]
3. Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.
González L; Akesolo U; Jiménez RM; Alonso RM
Electrophoresis; 2002 Jan; 23(2):223-9. PubMed ID: 11840527
[TBL] [Abstract][Full Text] [Related]
4. Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method.
Ferreirós N; Iriarte G; Alonso RM; Jiménez RM; Ortíz E
J Sep Sci; 2008 Mar; 31(4):667-76. PubMed ID: 18307163
[TBL] [Abstract][Full Text] [Related]
5. pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.
Cagigal E; González L; Alonso RM; Jiménez RM
J Pharm Biomed Anal; 2001 Oct; 26(3):477-86. PubMed ID: 11489393
[TBL] [Abstract][Full Text] [Related]
6. DEVELOPMENT AND VALIDATION OF HPLC ANALYTICAL METHODS USED-FOR DETERMINATION OF ASSAY, CONTENT UNIFORMITY AND DISSOLUTION OF IMMEDIATE RELEASE CANDESARTAN CILEXETIL 32 MG TABLETS.
Yuce M; Capan Y
Acta Pol Pharm; 2017 Mar; 74(2):357-367. PubMed ID: 29624240
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a high-performance liquid chromatographic method for determination of eprosartan in bulk drug and tablets.
Patel HU; Suhagia BN; Patel CN
J AOAC Int; 2010; 93(6):1862-7. PubMed ID: 21313813
[TBL] [Abstract][Full Text] [Related]
8. Determination of losartan, telmisartan, and valsartan by direct injection of human urine into a column-switching liquid chromatographic system with fluorescence detection.
del Rosario Brunetto M; Contreras Y; Clavijo S; Torres D; Delgado Y; Ovalles F; Ayala C; Gallignani M; Estela JM; Martin VC
J Pharm Biomed Anal; 2009 Sep; 50(2):194-9. PubMed ID: 19446420
[TBL] [Abstract][Full Text] [Related]
9. Behavior of sartans (antihypertensive drugs) in wastewater treatment plants, their occurrence and risk for the aquatic environment.
Bayer A; Asner R; Schüssler W; Kopf W; Weiß K; Sengl M; Letzel M
Environ Sci Pollut Res Int; 2014 Sep; 21(18):10830-9. PubMed ID: 24898294
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
Shetty SS; DelGrande D
J Pharmacol Exp Ther; 2000 Jul; 294(1):179-86. PubMed ID: 10871310
[TBL] [Abstract][Full Text] [Related]
11. Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection.
Piao ZZ; Lee ES; Tran HT; Lee BJ
Arch Pharm Res; 2008 Aug; 31(8):1055-9. PubMed ID: 18787797
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
[TBL] [Abstract][Full Text] [Related]
13. Palatability of angiotensin II antagonists among nephropathic children.
Meier CM; Simonetti GD; Ghiglia S; Fossali E; Salice P; Limoni C; Bianchetti MG;
Br J Clin Pharmacol; 2007 May; 63(5):628-31. PubMed ID: 17302913
[TBL] [Abstract][Full Text] [Related]
14. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
Taavitsainen P; Kiukaanniemi K; Pelkonen O
Eur J Clin Pharmacol; 2000 May; 56(2):135-40. PubMed ID: 10877007
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
[TBL] [Abstract][Full Text] [Related]
16. A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan.
Gopireddy RR; Maruthapillai A; Mahapatra S
J Chromatogr Sci; 2024 Feb; 62(2):147-167. PubMed ID: 35830866
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard.
Prasaja B; Sasongko L; Harahap Y; Hardiyanti ; Lusthom W; Grigg M
J Pharm Biomed Anal; 2009 Apr; 49(3):862-7. PubMed ID: 19217738
[TBL] [Abstract][Full Text] [Related]
18. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
19. Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan.
Bhuiyan MA; Hossain M; Nakamura T; Ozaki M; Nagatomo T
J Pharmacol Sci; 2010; 112(4):459-62. PubMed ID: 20308802
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
Belz GG; Breithaupt-Grögler K; Butzer R; Fuchs W; Hausdorf C; Mang C
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):336-41. PubMed ID: 11967820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
